TRB-001 safety and immune response in early Parkinson's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, double-blind, placebo-controlled, dose-finding Phase 1b trial in adults with early idiopathic Parkinson's disease. Participants will receive TRB-001 or placebo to evaluate safety, immunogenicity, and pharmacodynamics over a defined period. The study includes a few dose levels to identify any dose-response relationships while monitoring for adverse events and immune markers. Eligible patients are aged 40–75 with PD diagnosed within the last four years and stable concomitant PD medications if applicable. The trial is conducted at a single site in Vienna, led by Tridem Bioscience FlexCo.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Female or male patients aged 40-75 years old. Refer to section 5.3 for reproductive criteria for male and female participants
2. Diagnosed with idiopathic PD within the previous 4 years based on the MDS-PD criteria. The diagnosis must be confirmed by bradykinesia plus one of the other cardinal signs (resting tremor, rigidity or postural instability not caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction) being present
3. Severity ≤2 in the modified Hoehn and Yahr scale
4. Brain magnetic resonance imaging (MRI) results should be consistent with the diagnosis of PD
5. If on symptomatic PD medications (L-DOPA (+/- benserazide, carbidopa), COMT inhibitors (entacapone, opicapone), dopamine agonists (pramipexol, ropinirole, rotigotine, apomorphine), MAO-B inhibitors (safinamid, selegiline, rasagiline) or NMDA receptor antagonists (amantadine)), doses must be stable for at least 3 months before study entry
6. Understands and agrees to comply with the study procedures and provides written informed consent

Exclusion Criteria:

1. Known or suspected allergy, or history of anaphylaxis, to vaccines or their excipients, or kanamycin, if considered relevant by the investigator
2. Presence or history of autoimmune disease or immunodeficiency, if considered relevant by the investigator
3. Presence of active infectious disease (hepatitis B, hepatitis C, or human immunodeficiency virus (HIV))
4. Significant cognitive impairment or clinical dementia, or a Montreal Cognitive Assessment (MoCA) score \<26
5. High suspicion of other parkinsonian syndromes, such as multiple system atrophy, progressive supranuclear palsy, drug induced Parkinsonism and post-encephalitic Parkinsonism
6. Any relevant systemic illness. This includes cardiovascular, hepatic, gastroenterological, respiratory, endocrinological, hematologic disease, or any other condition that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study, unless patient has been on stable doses of medication for any of these concurrent illnesses for at least 3 months prior to study entry
7. Unstable psychiatric illness, including psychosis, suicidal ideation, untreated major depression, schizophrenia, or bipolar affective disorder within 90 days before Visit 1, as determined by the investigator
8. History of drug or alcohol abuse within the past 5 years
9. Recent history (≤2 years) of cancer (exceptions: basal cell carcinoma, intraepithelial cervical neoplasia)
10. Contraindication for MRI or lumbar puncture
11. Female patients who are pregnant or lactating
12. Birthmarks, tattoos, wounds, or skin conditions that may obscure the assessment of injection site reactions
13. Participation in the active treatment phase of any non-PD clinical trial within 30 days prior to Visit 1
14. Prior treatment with experimental immunotherapeutics for PD, immunosuppressive drugs or treatment with deep brain stimulation. Patient has received or plans to receive any vaccine other than study intervention within 28 days before or 28 days after each study vaccination.
15. Employee at the study site, spouse/partner or relative of any study staff (e.g., investigator, sub-investigators, or study nurse) or relationship to the sponsor

Where it's running

• PROSENEX Studienzentrum an der ATOMOS Klinik Währing
  Vienna, Austria Recruiting

Study contacts

• Study coordinator: CEO Tridem
• Email: office@tridem.at
• Phone: +4368120664069

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Parkinson’s Risk in Gaucher Disease Type 1

  This study tests how Parkinson’s risk relates to GBA1-related Gaucher disease in adults over 40, by collecting detailed clinical data and samples for future research.

  Recruiting Icahn School of Medicine at Mount Sinai · New York, New York · NCT07886879

• Can the Ronnie Gardiner Method improve thinking and daily function in people with Parkinson’s

  In this 10-week program, adults with Parkinson’s disease will try the Ronnie Gardiner Method to see if it helps thinking, talking, movement, balance, and quality of life.

  Recruiting University Ghent · Ghent, Oost-Vlaanderen · NCT07863219

• Effects of excitatory and inhibitory LIFUS of GPi in Parkinson’s patients without DBS

  This study tests two deep-brain focused ultrasound patterns on people with Parkinson’s to see if they change task performance and tremor, compared with a sham stimulation.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07846007

• Capacitive-resistive radiofrequency therapy for people with Parkinson's disease

  This study tests four TECAR therapy protocols on the legs to see which best reduces muscle stiffness and improves walking in people with Parkinson's disease.

  Recruiting Universidad San Jorge · Zaragoza, Zaragoza · NCT07842926

• Bayesian optimization to tune DBS for better gait in Parkinson’s patients

  This study tests whether using Bayesian optimization can quickly find DBS settings that lengthen step length in people with Parkinson's who already have DBS in place.

  Recruiting Early Phase 1 University of Minnesota · Minneapolis, Minnesota · NCT07835308

• rTMS-primed self-controlled practice for people with Parkinson’s disease

  This study tests whether priming motor training with rTMS and letting people with Parkinson’s control their practice improves motor learning and motivation.

  Recruiting National Taiwan University Hospital · Taipei, Zhongzheng Dist. · NCT07832695

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.